



SPECIALTY MEDICATIONS

available through **Accredo Health Group, Inc., an Express Scripts specialty pharmacy**

Call toll-free (800) 803-2523, 8:00 am to 8:00 pm, eastern time, Monday through Friday, to confirm that your medication is covered.

Effective as of January 1, 2018

- ◆ *Abraxane*[®] (paclitaxel protein-bound particles) [PA]
- Actemra*[™] (tocilizumab) [PA] [QD] [ST]
- Actemra*[™] SQ (tocilizumab) [PA] [QD] [PICA] [ST]
- ◆ *Actimmune*[®] (interferon gamma-1b) [PA][PICA]
- ◆ *Adcetris*[®] (brentuximab vedotin) [PA]
- Adcirca*[®] (tadalafil) [PA] [ST] [QD]
- Adempas*[®] (riociguat) [PA]
- Advate*[®] (antihemophilic factor [recombinant]) [CPA]
- Adynovate*[™] (antihemophilic Factor VIII [recombinant]) [CPA]
- ◆ *Afinitor*[®] (everolimus) [PA] [QD] [PICA]
- Afstyla*[®] (antihemophilic Factor [recombinant]) [CPA]
- ◆ *Alcensa*[®] (alectinib) [PA] [PICA] [QD] [SF]
- Aldurazyme*[®] (laronidase) [CPA]
- Alphanate*[®] (antihemophilic factor [human]) [CPA]
- AlphaNine*[®] SD (coagulation factor IX [human]) [CPA]
- Alprolix*[™] (coagulation factor IX [recombinant]) [CPA]
- ◆ *Alunbrig*[™] (brigatinib) [PA] [PICA]
- Ampyra*[™] (dalfampridine) [PA] [QD]
- Apokyn*[®] (apomorphine hydrochloride) [QD]
- Aralast*[®] NP (alpha[1]-proteinase inhibitor [human]) [PA]
- ◆ *Aranesp*[®] (darbepoetin alfa) [PA] [PICA]
- Arcalyst*[®] (rilonacept) [PA] [QD] [PICA]
- **Arixtra*[®] (fondaparinux sodium) [PICA]
- ◆ *Arranon*[®] (nelarabine) [PA]
- ◆ *Arzerra*[®] (ofatumumab) [PA]
- Aubagio*[®] (teriflunomide) [PA] [ST]
- ◆ *Avastin*[®] (bevacizumab) [PA] [QD]
- Avonex*[®] (interferon beta-1a) [PA] [PICA]
- Azacitidine (GENERIC) [PA] [QD]
- Bebulin*[®] VH (factor IX complex) [CPA]
- ◆ *Bendeka*[™] (bendamustine) [PA]
- BeneFIX*[®] (coagulation factor IX [recombinant]) [CPA]
- Benlysta*[®] (belimumab) [PA]
- Berinert*[®] (c1 esterase inhibitor [human]) [PA] [QD]
- Betaseron[®] (interferon beta-1b) [PA] [PICA]
- Bethkis*[®] (tobramycin)
- Bexarotene* (GENERIC)
- Bivigam*[™] (immune globulin intravenous [human]) [PA]
- ◆ *Bosulif*[®] (bosutinib) [PA] [SF] [QD]
- Botox*[®] (botulinum toxin type A) [PA] [PICA]
- ◆ Capecitabine (GENERIC) [PICA]
- Carbaglu*[™] (carglumic acid)
- Carimune*[®] NF (immune globulin intravenous [human]) [PA]
- Cayston*[®] (aztreonam) [PA] [QD]
- Cerdelga*[®] (eliglustat tartrate)
- Cerezyme*[®] (imiglucerase) [CPA] [ST]
- Cimzia*[®] (certolizumab pegol) [ST] [PA] [QD] [PICA]
- Cinryze*[®] (c1 esterase inhibitor) [PA] [QD]
- ◆ *Cabometyx*[™] (cobozantinib) [PA][QD] [SF]
- Copaxone*[®] (glatiramer acetate) [PA] [PICA]
- Copegus*[®] (ribavirin) [PA] [SF]
- Corifact*[®] (factor XIII [human]) [CPA]
- Cosentyx*[®] (secukinumab) [PA] [PICA]
- ◆ *Cotellic*[®] (cobimetinib) [PA] [PICA] [QD]
- Cuvitru*[™] (immune globulin 20% [human])
- ◆ *Cyramza*[®] (ramucirumab) [PICA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

CytoGam[®] (cytomegalovirus immune globulin intravenous [human]) [CPA]
Cytovene[®] IV (ganciclovir sodium)
Daklinza[™] (daclatasvir) [PA] [QD] [SF]
 ◆ *Darzalex*[®] (daratumumab) [PA]
 ◆ Decitabine (GENERIC)
Duopa[®] (*levodopa/carbidopa*)
Dupixent[®] (dupilumab) [PA] [QD]
Dysport[®] (abobotulinumtoxinA) [PA]
Egrifta[®] (tesamorelin) [PICA]
Elaprase[®] (idursulfase) [CPA]
Elelyso[™] (taliglucerase alfa)
 ◆ *Eligard*[®] (leuprolide acetate) [PA][PICA]
Eloctate[™] (antihemophilic factor [recombinant]) [CPA]
 ◆ *Empliciti*[™] (elotuzumab) [PA]
Enbrel[®] (etanercept) [PA] [QD] [PICA][ST]
 *Enoxaparin sodium (GENERIC) [PICA]
Entyvio[®] (vedolizumab) [PA]
Epclusa[®] (sofosbuvir/velpatasvir) [PA][QD][SF]
 ◆ *Epogen*[®] (epoetin alfa) [PA] [PICA]
 Epoprostenol sodium (GENERIC) [ST]
 ◆ *Erbitux*[®] (cetuximab) [PA] [QD]
 ◆ *Erivedge*[™] (vismodegib) [PA] [QD] [SF]
Esbriet[®] (pirfenidone) [PA]
Euflexxa[®] (sodium hyaluronate) [PA] [QD]
Exjade[®] (deferasirox) [SF]
Extavia[®] (interferon beta-1b) [ST] [PA] [PICA]
Eylea[™] (aflibercept) [PA]
Fabrazyme[®] (agalsidase beta) [CPA]
 ◆ *Farydak* (panobinostat) [PA] [PICA] [QD]
Feiba[®] VH (anti-inhibitor coagulant complex) [CPA]
Firazyr[®] (icatibant) [PA] [QD] [PICA]
 ◆ *Firmagon*[®] (degarelix) [PA] [PICA]
Flebogamma[®] (immune globulin [human]) [PA]
Flolan[®] (epoprostenol sodium) [PA]
 ◆ *Folotyng*[™] (pralatrexate) [PA]
 *Fondaparinux sodium (GENERIC) [PICA]
Forteo[®] (teriparatide [rDNA origin]) [PA] [PICA]
 **Fragmin*[®] (dalteparin sodium) [PICA]

GamaSTAN[®] S/D (immune globulin [human])
Gammagard[®] *Liquid* (immune globulin [human]) [PA]
Gammagard[®] S/D (immune globulin [human]) [PA]
Gammaked[™] (immune globulin, gamma caprylate [IGG]) [PA]
Gammaplex[®] (immune globulin [human]) [PA]
Gamunex[®] (immune globulin [human]) [PA]
 Ganciclovir (GENERIC)
Gattex[®] (teduglutide)
 ◆ *Gazyva*[™] (obinutuzumab) [PA]
Gel-One[®] (hyaluronate sodium) [PA]
Gelsyn-3[™] (hyaluronate sodium) [PA]
Genotropin[®] (somatropin [rDNA origin]) [PA] [PICA]
Gilenya[™] (afatinib) [PA] [ST]
 ◆ *Gilotrif*[™] (afatinib) [PA] [PICA] [QD]
Glassia[™] (alpha [1]-proteinase inhibitor [human]) [PA] [ST]
 Glatiramer (GENERIC) [PA] [PICA]
Glatopa[®] (glatiramer acetate) [PA] [PICA]
 ◆ *Granix*[™] (tbo-filgrastim) [PA] [PICA]
Haegarda[®] (c1 esterase inhibitor) [PA] [PICA]
 ◆ *Halaven*[™] (eribulin mesylate) [PA]
Harvoni[™] (ledipasvir/sofosbuvir) [PA] [QD] [SF]
Helixate[®] FS (antihemophilic factor [recombinant]) [CPA]
Hemofil[®] M (antihemophilic factor [human]) [CPA]
 ◆ *Herceptin*[®] (trastuzumab) [PA]
Hetlioz[™] (tasimelteon) [PA]
Hizentra[™] (immune globulin subcutaneous [human]) [PA]
H.P. Acthar[®] *Gel* (corticotropin) [PA] [QD]
Humate-P[®] (antihemophilic factor/von Willebrand factor complex [human]) [CPA]
Humatrope[®] (somatropin [rDNA origin]) [PA] [PICA]
Humira[®] (adalimumab) [PA] [QD] [PICA]
Hyalgan[®] (sodium hyaluronate) [PA] [QD]
 ◆ *Hycamtin*[®] capsules (topotecan) [PA]
Hymovis[®] (hyaluronate sodium) [PA]
HyperRho[®] S/D (Rho[D] immune globulin [human])

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

Hyqvia[™] (immune globulin infusion 10% [human] with recombinant) [PA]
 ◆ *Ibrance*[®] (palbociclib) [PA] [PICA] [QD]
Idelvion[®] (coagulation factor IX [recombinant]) [CPA]
 ◆ *Idhifa*[®] (enasidenib) [PICA]
Ilaris[®] (canakinumab) [PA] [QD]
Iluvien[®] (Fluocinolone)
 ◆ Imatinib (GENERIC) [PA] [PICA] [QD]
 ◆ *Imfinzi*[™] (durvalumab) [PA]
Increlex[®] (mecasermin [rDNA origin]) [PA] [PICA]
Inflextra[™] (infliximab-dyyb) [PA] [ST]
 ◆ *Inlyta*[®] (axitinib) [PA] [QD] [PICA] [SF]
 ◆ *Intron*[®] A (interferon alfa-2b) [PA] [PICA]
 **Iprivask*[®] (desirudin)
 ◆ *Iressa*[®] [PA] [PICA] [QD] [SF]
 ◆ *Istodax*[®] (romidepsin) [PA] [QD]
 ◆ *Ixempra*[®] (ixabepilone) [PA]
Ixinity[®] (coagulation factor IX [recombinant]) [CPA]
Jadenu[™] (deferasirox) [SF]
 ◆ *Jakafi*[™] (ruxolitinib) [PA] [SF] [QD]
 ◆ *Jevtana*[®] (cabazitaxel) [PA] [QD]
Juxtapid[®] (lomitapide)
 ◆ *Kadcyla*[™] (ado-trastuzumab emtansine) [PA]
Kalbitor[®] (ecallantide) [PA] [QD]
Kalydeco[™] (ivacaftor) [PA] [SF]
Kanuma[™] (sebelipase alfa)
Kevzara[®] (sarilumab) [QD] [PA] [PICA]
 ◆ *Kisqali*[®] (ribociclib) [PA] [QD] [PICA]
Kitabis Pak[®] (Tobramycin)
Koate[®]-DVI (antihemophilic factor [human]) [CPA]
Kogenate[®] FS (antihemophilic factor [recombinant]) [CPA]
Kovaltry[®] (antihemophilic factor VIII) [CPA]
Krystexxa[™] (pegloticase) [PA]
Kuvan[®] (sapropterin dihydrochloride) [PA]
Kynamro[™] (mipomersen sodium)
 ◆ *Lartruvo*[™] (olaratumab) [PA]
Lemtrada[™] (alemtuzumab) [PA]
 ◆ *Lenvima*[™] (lenvatinib) [PA] [PICA] [SF]

Letairis[®] (ambrisentan) [PA] [QD]
 ◆ *Leukine*[®] (sargramostim) [PA] [PICA]
 Leuprolide acetate (GENERIC) [PICA]
Liletta[™] (levonorgestrel-releasing intrauterine device)
 ◆ *Lonsurf*[®] (tipiracil/trifluridine) [PA] [PICA]
 **Lovenox*[®] (enoxaparin sodium) [PICA]
Lucentis[®] (ranibizumab) [PA]
Lumizyme[™] (alglucosidase alfa) [CPA]
Lupaneta[™] (leuprolide acetate) [PICA]
Lupron Depot[®] (leuprolide acetate) [PA] [PICA]
Lupron Depot-PED[®] (leuprolide acetate) [PA] [PICA]
 ◆ *Lynparza*[™] (olaparib) [PA] [SF] [PICA]
Macugen[®] (pegaptanib sodium injection) [PA]
Makena[™] (hydroxyprogesterone caproate) [PA]
Mavyret[™] (glecaprevir/pibrentasvir) [QD] [SF] [PA]
 ◆ *Mekinist*[™] (trametinib) [PA] [PICA] [QD]
MICRhoGAM[®] (Rho[D] immune globulin [human])
 Mitoxantrone HCl (GENERIC)
Moderiba[™] (ribavirin) [PA]
Monoclate-P[®] (antihemophilic factor [human]) [CPA]
Mononine[®] (coagulation factor IX [human]) [CPA]
 ◆ *Mozobil*[®] (plerixafor) [QD] [PA] [PICA]
Myalept[™] (metreleptin) [PA] [PICA]
Myobloc[®] (botulinum toxin type B) [PA] [PICA]
Naglazyme[®] (galsulfase) [CPA]
Natpara[®] (parathyroid hormone) [PA] [PICA]
 ◆ *Nerlynx*[™] (neratinib) [PICA]
 ◆ *Neulasta*[®] (pegfilgrastim) [PA] [PICA]
Neumega[®] (oprelvekin) [PICA]
 ◆ *Neupogen*[®] (filgrastim) [PA] [PICA]
 ◆ *Nexavar*[®] (sorafenib) [PA] [QD] [PICA] [SF]
 ◆ *Ninlaro*[®] (ixazomib) [PA] [PICA] [QD]
Norditropin[®] (somatropin [rDNA origin]) [PA] [PICA]
Norditropin/Nordiflex[®] (somatropin [rDNA origin]) [PA] [PICA]
Northera[®] (droxidopa) [PA]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

NovoEight[®] (antihemophilic factor VIII [recombinant]) [CPA]
NovoSeven[®] *RT* (coagulation factor VIIa [recombinant]) [CPA]
Nplate[®] (romiplostim) [PA]
Nucala[™] (mepolizumab) [PA]
Nuplazid[™][SF]
Nutropin[®] (somatropin [rDNA origin]) [PA] [PICA]
Nutropin AQ[®] (somatropin [rDNA origin]) [PA] [PICA]
Nuwiq[®] (antihemophilic Factor VIII [recombinant]) [CPA]
Ocaliva[™](obeticholic acid) [PA][QD]
Ocrevus[™](ocrelizumab) [PA] [ST]
Octagam[®] (immune globulin intravenous [human]) [PA]
 Octreotide acetate (GENERIC)
 ♦ *Odomzo*[®] (*sonidegib*) [PA][PICA]
Ofev[®] (Nintedanib) [PA]
Olysio[™] (simeprevir) [PA] [SF]
Omnitrope[®] (somatropin) [PA] [PICA]
 ♦ *Opdivo*[®] (Nivolumab) [PA]
Opsumit[®] (macitentan) [PA]
Orencia[®] *IV* (abatacept intravenous) [PA] [PICA]
Orencia[®] *SC* (abatacept subcutaneous) [ST] [PA] [QD] [PICA]
Orenitram[™] (treprostinil) [PA]
Orkambi[®] (lumacaftor/ivacaftor) [PA]
OrthoVisc[®] (hyaluronate sodium) [PA]
Otezla[®] (apremilast) [PA] [ST]
Ozurdex[™] (dexamethasone)
 ♦ *Pegasys*[®] (peginterferon alfa-2a) [PA] [PICA] [SF]
 ♦ *Perjeta*[™] (pertuzumab) [PA]
Plegridy[™] (peginterferon Beta-1A) [PA] [PICA]
 ♦ *Pomalyst*[®] (pomalidomide) [PA] [PICA]
 ♦ *Portrazza*[®] (necitumumab) [PICA]
Praluent[®] (alirocumab) [PA]
Privigen[®] (immune globulin intravenous [human]) [PA]
 ♦ *Procrit*[®] (epoetin alfa) [PA] [PICA]
Procysbi[™] (cysteamine bitartrate)
Profilnine[®] *SD* (factor IX complex [human]) [CPA]
 ♦ *Proleukin*[®] (aldesleukin) [PA]
Prolia[™] (denosumab) [PA] [QD]
Promacta[®] (eltrombopag) [PA] [QD]
ProThelial[™] (sucralfate)
Pulmozyme[®] (dornase alfa)
Ravicti[™] (glycerol phenylbuterate)
Rebetol[®] (ribavirin) [PA]
Rebif[®] (interferon beta-1a) [PA] [PICA]
Recombinate[™] (antihemophilic factor [recombinant]) [CPA]
Remicade[®] (infliximab) [PA]
Remodulin[®] (treprostinil sodium) [ST]
Repatha[™](evolocumab) [PA]
Retisert[®] (fluocinolone acetonide) [QD]
Revatio[®] *injection* (sildenafil citrate) [PA] [QD]
Revatio[®] *tablets* (sildenafil citrate) [PA] [QD]
 ♦ *Revlimid*[®] (lenalidomide) [PA] [QD] [PICA]
RhoGAM[®] (RHo[D] immune globulin [human])
Rhophylac[®] (RHo[D] immune globulin intravenous [human])
RiaSTAP[®] (fibrinogen)
RibaPak[®] (GENERIC) [PA]
Ribasphere[®] (GENERIC) [PA] [SF]
Ribavirin (GENERIC) [PA] [SF]
 ♦ *Rituxan*[®] (rituximab) [PA]
Rixubis[™] (coagulation factor IX [recombinant]) [CPA]
Ruconest[™] (c1 Esterase Inhibitor [recombinant]) [PA]
 ♦ *Rydapt*[®] (midostaurin) [PA]
Sabril[®] (vigabatrin)
Saizen[®] (somatropin [rDNA origin]) [PA] [PICA]
Samsca[®] (tolvaptan) [QD]
Sandostatin[®] (octreotide acetate) [PICA]
Sandostatin LAR[®] (octreotide/IM) [PICA]
Serostim[®] (somatropin [rDNA origin]) [PA] [PICA]
Signifor[®] (pasireotide dispartate) [PA]
Signifor[®] *LAR* (pasireotide pamoate) [PA] [PICA]
Sildenafil (GENERIC) [ST] [QD]

♦ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

Siliq (brodalumab)[™] [QD] [PA] [PICA]
Simponi[™] (golimumab) [ST] [PA] [QD] [PICA]
Simponi[™] ARIA[™] (golimumab) [ST] [PA] [QD] [PICA]
Soliris[®] (eculizumab)
Somatuline Depot[®] (lanreotide) [PICA]
Somavert[®] (pegvisomant)
Sovaldi[™] (sofosbuvir) [PA] [QD] [SF]
Spinraza[™] (nusinersen) [PA]
♦ *Sprycel*[®] (dasatinib) [PA] [QD] [PICA] [SF]
Stelara[™] (ustekinumab) [PA] [QD] [PICA]
Stimate[®] (desmopressin acetate)
♦ *Stivarga*[®] (regorafenib) [PA] [QD]
Supartz[®] (sodium hyaluronate) [PA] [QD]
Supprelin[®] LA (histrelin acetate)
♦ *Sutent*[®] capsules (sunitinib malate) [PICA] [QD]
Sylatron[™] (peginterferon alfa-2b)
Sylvant[™] (siltuximab)
Synagis[®] (palivizumab) [PA] [QD]
Synvisc[®]/Synvisc-ONE[®] (hylan G-F 20) [PA] [QD]
♦ *Tafinlar*[®] (dabrafenib) [PA] [PICA] [QD] [SF]
♦ *Tagrisso*[™] (osimertinib) [PA] [PICA] [QD]
Taltz[®] (ixekizumab) [PA] [QD] [PICA] [ST]
♦ *Tarceva*[®] (erlotinib) [PA] [QD] [PICA] [SF]
♦ *Tasigna*[®] (nilotinib) [PA] [QD] [PICA] [SF]
♦ *Tecentriq*[™] (atezolizumab) [PA]
Tecfidera[™] (dimethyl fumarate) [PA] [ST]
Technivie[™] (ombitasvir/paritaprevir/ritonavir) [PA] [SF]
♦ *Temodar*[®] (temozolomide) [PA] [PICA]
Temozolomide (GENERIC) [PICA]
Tetrabenazine (GENERIC)
♦ *Thalomid*[®] (thalidomide) [PA] [PICA]
Tobi[®] (tobramycin)
Tobi-Podhaler[®] (tobramycin)
Tobramycin (GENERIC)
♦ *Torise*[®] (temsiriolimus) [PA]
Tracleer[®] (bosentan) [PA] [QD]
♦ *Treanda*[®] (bendamustine) [PA]
Tremfya[™] (guselkumab) [PA] [ST] [PICA]

Tretten[®] (coagulation factor XIII A-subunit [recombinant]) [CPA]
♦ *Tykerb*[®] (lapatinib) [PA] [QD] [PICA]
Tymlos[™] (abaloparatide) [PA] [PICA]
Tysabri[®] (natalizumab) [PA] [QD]
Tyvaso[®] (treprostinil) [PA]
Uptravi[®] (selexipag)
♦ *Valchlor*[™] (mechlorethamine) [PA]
♦ *Vantas*[®] (histrelin) [PA]
♦ *Vectibix*[®] (panitumumab) [PA]
♦ *Velcade*[®] (bortezomib) [PA]
Veletri[®] (epoprostenol sodium)
Veltassa[™] (paitromer)
Ventavis[®] (iloprost) [PA] [QD]
♦ *Verzenio*[™] (abemaciclib) [PICA] [SF]
♦ *Vidaza*[®] (azacitidine) [PA] [QD] [PICA]
Viekira Pak (ombitasvir/paritaprevir/ritonavir co-packed with dasabuvir) [PA] [QD] [SF]
Vigabatrin (GENERIC)
Vimizim[™] (elosulfase alfa) [CPA]
Visudyne[®] (verteporfin)
Vivitrol[®] (naltrexone)
Vosevi[®] (sofosbuvir/velpatasvir/voxilaprevir) [QD] [SF] [PA]
♦ *Votrient*[®] (pazopanib) [PA] [QD] [PICA] [SF]
Vpriv[™] (velaglucerase alfa) [CPA]
Wilate[®] (von Willebrand factor/coagulation factor VIII complex [human]) [CPA]
WinRho SDF[®] (Rho[D] immune globulin intravenous [human])
♦ *Xalkori*[®] (crizotinib) [PA] [QD] [PICA] [SF]
Xeljanz[®] (tofacitinib citrate) [PA]
Xeljanz XR[®] (tofacitinib) [PA]
Xenazine[®] (tetrabenazine) [PA] [QD] [SF]
Xeomin[®] (incobotulinumtoxinA) [PA]
♦ *Xgeva*[™] (denosumab) [QD]
Xolair[®] (omalizumab) [PA] [QD]
♦ *Xtandi*[®] (enzalutamide) [PA] [QD] [SF]
Xyntha[®] (antihemophilic factor [recombinant]) [CPA]

♦ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.

- ◆ *Yervoy*[™] (ipilimumab) [PA] [QD]
- ◆ *Zaltrap*[®] (afibercept) [PA]
- ◆ *Zarxio* (GENERIC) [PA] [PICA]
- Zavesca*[®] (miglustat) [QD][CPA]
- ◆ *Zelboraf*[™] (vemurafenib) [PA] [QD] [PICA] [SF]
- Zemaira*[®] (alpha [1]-proteinase inhibitor [human])
[PA]
- Zepatier*[™] (elbasvir/grazoprevir) [PA] [QD] [SF]
- Zinbryta*[™] (daclizumab) [PA] [PICA]
- ◆ *Zoladex*[®] (goserelin acetate) [PA] [PICA]
- ◆ *Zolinza*[®] (vorinostat) [PA] [QD] [PICA] [SF]
- Zomactor*[®] (somatropin [rDNA origin]) [PA] [PICA]
- Zorbtive*[®] (somatropin [rDNA origin]) [PA] [PICA]
- ◆ *Zykadia*[™] (ceritinib) [PA] [PICA] [QD] [SF]
- ◆ *Zytiga*[™] (abiraterone acetate) [PA] [QD] [PICA]
[SF]

◆ If the indication is CANCER, and the drug is subject to management by EviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization.

*This specialty drug may be filled two (2) times at a retail pharmacy on an emergency basis. Subsequent fills must be made through Accredo's mail order delivery.

[PICA] = Specialty drug is available through the NYC Municipal Program called PICA. NYC Municipal employees can contact Accredo Customer Service at (800) 467-2006 and inquire about drug coverage.

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program.

The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program.

The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program.

The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program.

The symbol [SF] next to a drug name indicates that this medication is subject to the Split-Fill Program.

All rights in the product names of all third-party products listed, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. Subject to change.